Consensus PTC Therapeutics, Inc. Berne S.E.

Stocks

P91

US69366J2006

Pharmaceuticals

Delayed Berne S.E. Other stock markets			5-day change	1st Jan Change
- ^CHF	-.--%		-.--%	-

06-16	PTC Therapeutics Prices $500 Million Notes Offering	MT
06-15	PTC Therapeutics Plans $500 Million Convertible Notes Offering to Refinance 2026 Notes	MT

Evolution of the Average Target: PTC Therapeutics, Inc.

Evolution of the Target Price: PTC Therapeutics, Inc.

Changes in Analyst Recommendations: PTC Therapeutics, Inc.

e07f2f24032da42e1ed2193ef5b7c.fIrKxy_HJbIdP8szfIkDC0gJ-VXXDJmr1RTxFwNNds8.FL7-jFW1ctZXerpsDb5ZMhF-nBfiTfXfuF3BdEofB50p2fmGTpJGwUhnpA~a912489be6dd6fa1740fff3892c9123c

Analysts' recommendations: PTC Therapeutics, Inc.

06-09	PTC Therapeutics Shares Rise After Upgrade From Citigroup	MT
06-09	Citigroup Upgrades PTC Therapeutics to Buy From Hold, Raise Price Target to $108 From $76	MT
05-08	TD Cowen Upgrades PTC Therapeutics to Buy From Hold, Adjusts Price Target to $90 From $75	MT
04-07	RBC Adjusts Price Target on PTC Therapeutics to $81 From $82, Maintains Sector Perform Rating	MT
02-23	Morgan Stanley Lifts Price Target on PTC Therapeutics to $92 From $90, Keeps Overweight Rating	MT
02-20	RBC Cuts Price Target on PTC Therapeutics to $82 From $87, Keeps Sector Perform Rating	MT
01-08	RBC Lowers Price Target on PTC Therapeutics to $87 From $91, Keeps Sector Perform Rating	MT
12-01	PTC Therapeutics Shares Drop After RBC Downgrade	MT
12-01	RBC Downgrades PTC Therapeutics to Sector Perform From Outperform, Lifts Price Target to $91 From $82	MT
11-05	RBC Capital Adjusts PTC Therapeutics Price Target to $82 From $70, Maintains Outperform Rating	MT
25-10-08	RBC Raises Price Target on PTC Therapeutics to $70 From $63, Keeps Outperform Rating	MT
25-08-08	RBC Raises Price Target on PTC Therapeutics to $63 From $60, Keeps Outperform Rating	MT
25-08-08	Morgan Stanley Raises Price Target on PTC Therapeutics to $76 From $70, Keeps Overweight Rating	MT
25-07-29	UBS Adjusts Price Target on PTC Therapeutics to $80 From $71, Maintains Buy Rating	MT
25-07-29	Truist Raises Price Target on PTC Therapeutics to $86 From $80, Keeps Buy Rating	MT
25-06-04	RBC Raises Price Target on PTC Therapeutics to $60 From $58, Keeps Outperform Rating	MT
25-05-09	BofA Upgrades PTC Therapeutics to Buy From Neutral, Adjusts Price Target to $68 From $55	MT
25-05-07	Citigroup Upgrades PTC Therapeutics to Neutral From Sell, Adjusts Price Target to $40 From $50	MT
25-05-05	RBC Capital Adjusts PTC Therapeutics Price Target to $57 From $65, Maintains Outperform Rating	MT
25-04-03	RBC Lifts Price Target on PTC Therapeutics to $65 From $64, Keeps Outperform Rating	MT
25-02-28	RBC Capital Adjusts PTC Therapeutics Price Target to $64 From $63, Maintains Outperform Rating	MT
25-02-18	RBC Capital Adjusts PTC Therapeutics Price Target to $63 From $60, Maintains Outperform Rating	MT
25-01-07	RBC Cuts Price Target on PTC Therapeutics to $58 From $63, Keeps Outperform Rating	MT
24-12-13	Morgan Stanley Upgrades PTC Therapeutics to Overweight From Equalweight, Raises Price Target to $67 From $45	MT
24-12-03	UBS Raises PTC Therapeutics Price Target to $71 From $47, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+10.94%
	JOHNSON & JOHNSON					+10.72%
	ABBVIE INC.					+17.12%
	ROCHE HOLDING AG					+12.21%
	ASTRAZENECA PLC					+26.26%
	NOVARTIS AG					+5.72%
	NOVO NORDISK A/S					+7.33%
	AMGEN INC.					+4.49%
	GILEAD SCIENCES, INC.					+27.32%
	Average					+13.57%
	Weighted average by Cap.					+12.76%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

78.98USD

Average target price

93.93USD

Spread / Average Target

+18.93%

High Price Target

124.00USD

Spread / Highest target

+57.00%

Low Price Target

65.00USD

Spread / Lowest Target

-17.70%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Citigroup
TD Cowen
RBC Capital Markets
Morgan Stanley
UBS
Truist Securities
BofA Securities
Goldman Sachs
Raymond James
Cantor Fitzgerald
Barclays
JPMorgan Chase
Credit Suisse
SVB Securities LLC
Jefferies & Co.